Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Carroll

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
The Journal of Urology|January 13, 2019
Editorial CommentPeter Carroll
The Journal of Urology|December 9, 2022
Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. ReplyPeter Carroll
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2003
PCR patent issuesPeter Carroll, David Casimir
The Journal of Urology|November 2, 2020
Editorial CommentCarissa Chu, Peter Carroll
The Journal of Urology|April 6, 2019
Editorial CommentPeter Carroll, Bogdana Schmidt
Clinical Medicine (London, England)|May 7, 2002
Doctors, patients and the Internet: time to grasp the nettleSanjay Sastry, Peter Carroll
The Journal of Urology|June 17, 2015
What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?Marc Dall'Era, Peter Carroll
The Journal of Urology|June 11, 2005
Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE databasePeter Langenstroer, Peter Carroll, J Brantley Thrasher
BJU International|November 6, 2009
Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSUREDavid Aaronson, Janet Cowan, Peter Carroll, et al.
BJU International|February 18, 2009
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapyJared Whitson, Anna Berry, Peter Carroll, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
The Journal of Urology|January 13, 2019
Editorial CommentPeter Carroll
The Journal of Urology|December 9, 2022
Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. ReplyPeter Carroll
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2003
PCR patent issuesPeter Carroll, David Casimir
The Journal of Urology|November 2, 2020
Editorial CommentCarissa Chu, Peter Carroll
The Journal of Urology|April 6, 2019
Editorial CommentPeter Carroll, Bogdana Schmidt
Clinical Medicine (London, England)|May 7, 2002
Doctors, patients and the Internet: time to grasp the nettleSanjay Sastry, Peter Carroll
The Journal of Urology|June 17, 2015
What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?Marc Dall'Era, Peter Carroll
The Journal of Urology|June 11, 2005
Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE databasePeter Langenstroer, Peter Carroll, J Brantley Thrasher
BJU International|November 6, 2009
Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSUREDavid Aaronson, Janet Cowan, Peter Carroll, et al.
BJU International|February 18, 2009
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapyJared Whitson, Anna Berry, Peter Carroll, et al.
Pageof 8